EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A BALB/c mouse model of Mycobacterium abscessus lung infection based on once-weekly cyclophosphamide administration

Binayak Rimal iD, Chandra M Panthi, Ruth A Howe, Gyanu Lamichhane iD

Disease Models & Mechanisms · 2025

DOI: 10.1242/dmm.052310 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Disease Models & Mechanisms, 2025. Verfasst von Binayak Rimal und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD 21287, USA. Hauptthemen laut MEDLINE: Cyclophosphamide, Mycobacterium abscessus, Mycobacterium Infections, Nontuberculous, Lung. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, Johns Hopkins University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycobacterium abscessus is a fast-growing non-tuberculous mycobacterium that can cause chronic lung disease leading to rapid decline in lung function. There are no FDA-approved therapies for this disease. To support the development of new treatments, an animal model of M. abscessus lung infection that is simple to implement and requires minimal resources is crucial to encourage broad adoption. We present a mouse model using the immunocompetent BALB/c strain, which is both widely available and cost effective. Since BALB/c mice naturally clear M. abscessus infections, immunosuppression is necessary to sustain bacterial growth in the lungs. Once-weekly intraperitoneal injections of the immunosuppressant cyclophosphamide at 250 mg/kg successfully induced proliferation of M. abscessus during the acute phase, followed by stabilization characteristic of chronic infection. This model demonstrated the efficacy of imipenem – an antibiotic commonly used in clinical settings – by significantly reducing bacterial burdens, mirroring their effects in human cases. However, clofazimine, which is also used to treat this disease, was bacteriostatic. This cost-effective and accessible mouse model is suitable for diverse laboratory environments and provides a valuable tool for preclinical evaluation of treatments for M. abscessus lung disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CyclophosphamideMycobacterium abscessusMycobacterium Infections, NontuberculousLungLung DiseasesAnimalsDisease Models, AnimalMice, Inbred BALB CMiceFemaleImipenemAnti-Bacterial AgentsClofazimineDrug Administration Schedule

Stichwörter der Autor:innen

Mycobacterium abscessusMycobacteroides abscessusLung infectionMouse model

Substanzen

CyclophosphamideImipenemAnti-Bacterial AgentsClofazimine

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD 21287, USA.
  • Center for Nontuberculous Mycobacteria and Bronchiectasis, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD 21287, USA.

ORCID-Profile: Binayak Rimal, Gyanu Lamichhane

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • Johns Hopkins University
  • National Institutes of Health

Zitieren

APA

Rimal, B., Panthi, C. M., Howe, R. A., & Lamichhane, G. (2025). A BALB/c mouse model of Mycobacterium abscessus lung infection based on once-weekly cyclophosphamide administration. Disease Models & Mechanisms. https://doi.org/10.1242/dmm.052310

Vancouver

Rimal B, Panthi CM, Howe RA, Lamichhane G. A BALB/c mouse model of Mycobacterium abscessus lung infection based on once-weekly cyclophosphamide administration. Disease Models & Mechanisms. 2025. doi:10.1242/dmm.052310

BibTeX
@article{Rimal2025,
  author = {Rimal, Binayak and Panthi, Chandra M and Howe, Ruth A and Lamichhane, Gyanu},
  title = {A BALB/c mouse model of Mycobacterium abscessus lung infection based on once-weekly cyclophosphamide administration},
  journal = {Disease Models & Mechanisms},
  year = {2025},
  doi = {10.1242/dmm.052310}
}
Kostenlos starten →